Top

Published in:

01-12-2014 | Gynecologic Oncology

HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma

Authors: Ioannis Kalogiannidis, Stamatios Petousis, Mattheos Bobos, Chrysoula Margioula-Siarkou, Maria Topalidou, Alexis Papanikolaou, Ignace Vergote, Theodoros Agorastos

Published in: Archives of Gynecology and Obstetrics | Issue 6/2014

Abstract

Purpose

Το define the prognostic significance of HER-2/neu and PTEN expression in patients with endometrioid (type I) endometrial cancer.

Methods

Seventy-seven patients with endometrioid endometrial carcinoma were included in the study, in a period between 1996 and 2009. Patients with coexisting malignancy and those having incomplete immunohistochemical data or clinical follow-up were excluded. Histological staging was defined according to the revised FIGO staging (2009). Clinico-pathologic and immunohistochemical characteristics were correlated in a multivariate Cox regression analysis with overall survival (OS), cancer-related survival (CRS) and disease-free survival (DFS).

Results

Mean age of the patients was 62.7 years. The median follow-up was 67 months (9–124 months). HER-2/neu expression was detected in 18.2 % (n = 14), and PTEN expression in 72.7 % (n = 56) of our patients. Multivariate Cox regression analysis showed that patient’s age, FIGO staging and HER-2/neu expression were independent prognostic factors for OS, CRS and DFS. PTEN expression did not significantly affect survival outcomes of the present study.

Conclusions

HER-2/neu but not PTEN expression is an independent prognostic factor for type I endometrial carcinoma.

Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB (2008) HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 32:307–316PubMed

Bąkiewicz A, Michalak J, Sporny S (2010) Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas. Pol J Pathol 61:185–191PubMed

Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF (2008) Gynecologic oncology group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 108:3–9 Epub 2007 Oct 18PubMedCentralPubMedCrossRef

Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8–13PubMed

Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, Makedos G (2006) Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet 274:91–96PubMedCrossRef

Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105:109PubMedCrossRef

Ayhan A, Taskiran C, Yuce K, Kucukali T (2002) The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma. Int J Gynecol Pathol 22:71–74CrossRef

Coronado PJ, Vidart JA, Lopez-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M (2001) P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 98:103–108PubMedCrossRef

Ryan AJ, Susil B, Jobling TW, Oehler MK (2005) Endometrial cancer. Cell Tissue Res 322:53–61PubMedCrossRef

10.

Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH (1999) HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 18:138–143PubMedCrossRef

11.

Benevolo M, Vocaturo A, Novelli F, Mariani L, Vocaturo G, Cianciulli AM et al (2007) Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. Anticancer Res 27:2839–2844PubMed

12.

Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T et al (2010) Expression of ER, PR, and HER-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev 11:215–220PubMed

13.

Jongen VH, Briët JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG (2009) Nijman HW aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer 19:670–676PubMedCrossRef

14.

Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59–65PubMedCrossRef

15.

Yao YY, Xu WZ, Wang Y, Shen DH, Wang JL, Wei LH (2011) Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma. Beijing Da Xue Xue Bao 43:743–748PubMed

16.

Inaba F, Kawamata H, Teramoto T, Fukasawa I, Inaba N, Fujimori T (2005) PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep 13:17–24PubMed

17.

Kanamori Y, Kigawa J, Itamochi H, Sultana H, Suzuki M, Ohwada M et al (2002) PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer 100:686–689PubMedCrossRef

18.

Athanassiadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiadou AM, Stamati PN, Patsouris E (2007) The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 17:697–704PubMedCrossRef

Title: HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma
Authors: Ioannis Kalogiannidis
Stamatios Petousis
Mattheos Bobos
Chrysoula Margioula-Siarkou
Maria Topalidou
Alexis Papanikolaou
Ignace Vergote
Theodoros Agorastos
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 6/2014
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-014-3333-2

At a glance: The STEP trials

Springer Medicine

HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2014

MR angiography demonstrates a positive correlation between placental blood vessel volume and fetal size

Do follicular fluid gelatinase levels affect fertilization rates and oocyte quality?

An unusual long-term complication of transobturator polypropylene mesh

Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET

Outcomes and complications of trans-vaginal mesh repair using the Prolift™ kit for pelvic organ prolapse at 4 years median follow-up in a tertiary referral centre

Herpes simplex virus type 2 and the risk of cervical cancer: a meta-analysis of observational studies